{"id":"W4402031327","doi":"10.1016/j.jtct.2024.08.015","title":"CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis","year":2024,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; NYU Grossman School of Medicine; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; Amgen; Rush University; HistoGenetics; U.S. Public Health Service; U.S. Department of Defense; Sanofi; GlaxoSmithKline; National Institute on Aging; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Navy; Gateway for Cancer Research; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences","keywords":"Propensity score matching; Regimen; Medicine; Internal medicine; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001903358,0.0006023398,0.001139724,0.0006735923,0.0005801074,0.001659801,0.0007532548,0.00060029,0.00621739],"category_scores_gemma":[0.00365904,0.0004260821,0.002788524,0.001090106,0.0003574491,0.0009696669,0.0008349268,0.001718735,0.0006583165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004909304,"about_ca_system_score_gemma":0.0009795896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001624846,"about_ca_topic_score_gemma":0.002620257,"domain_scores_codex":[0.9981378,0.00052215,0.0001773503,0.0005298067,0.0003118626,0.0003210556],"domain_scores_gemma":[0.9982293,0.0003865095,0.0005199402,0.0005028388,0.0001560404,0.0002054501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06340504,0.001328498,0.8398083,0.0003131976,0.01306647,0.000647501,0.0001837479,0.003877141,0.004438657,0.002102623,0.005529748,0.06529917],"study_design_scores_gemma":[0.005730098,0.009572481,0.9072224,0.0002117497,0.01781785,0.002058535,0.0006702963,0.03805074,0.002185982,0.00384333,0.01247898,0.0001575798],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892935,0.001564792,0.005038296,0.0001486375,0.0001442006,0.000149928,0.001101959,0.00004005364,0.002518608],"genre_scores_gemma":[0.9965495,0.0002851911,0.001006065,0.0001403538,0.00009167002,0.00005146299,0.0009924048,0.00003562498,0.0008477651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00621739,"threshold_uncertainty_score":0.02079922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1162576232521546,"score_gpt":0.3826355467407397,"score_spread":0.266377923488585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}